Did anyone else just find out at POA that we dropped the bipolar study? After they continuously talked about the “HUGE” opportunity there? And they acted like we already knew about it As if they had actually announced it?
Ummm this is public knowledge. It was also released in part of a press release in the previous quarterly earnings report. Way to pay attention r*****....now go back to work and shut up karen.
I never agree with this ass#ole but in this instance they are right. To the OP this was announced months ago. Don't post on this site if you are checked out and missing critically important information in real time as it comes in. On the topic of bipolar being nixed I think it was a great decision. We need to get away from the concept of selling directly against the same molecule. We can scream indication all we want but at the end of the day if we went in with a bipolar indication with OXR there would be a larger climb of share in OXC over OXR.
Agreed. Bipolar sounded nice in concept but safe to say if the potential return didn’t outweigh the cost of obtaining the indication. Hopefully the cash saved on trials opens the door for another potential psych asset acquisition as well.
When supernus had all of us calling on nurse practitioners in psych offices they all wrote significantly for myself as well as quite a few others I know. This would have been a great asset for the neuro group going over to psych in the next few years.
